science
Experimental Opioid Derivative DFNZ Shows Pain Relief Without Addiction or Respiratory Risks in Mouse Study
Researchers at the National Institute on Drug Abuse developed DFNZ, a derivative of nitazene compounds, which provided pain relief in mice for at least two hours without signs of addiction, tolerance, or breathing suppression. The study, published in Nature, suggests potential applications for treating chronic pain, surgical pain, and opioid use disorder.
neurosciencenews.comAudio version
Tap play to generate a narrated version.
A study examined nitazenes, a class of synthetic opioid compounds. Nitazenes were developed in the 1950s for potential pain relief but were abandoned due to their high potency, addictive properties, and overdose risks. They have appeared on the black market and are associated with illicit use.
The research team aimed to analyze the pharmacology of nitazenes and develop a less potent version for therapeutic use. They created DFNZ, a derivative of nitazenes.
In tests on mice, DFNZ delivered pain relief without signs of addiction, tolerance, or breathing suppression.
Findings on DFNZ Effects DFNZ did not exhibit addiction potential, respiratory depression, tolerance, or significant withdrawal effects in the mice.
Opioid pain medications are essential for medical purposes but can lead to addiction and overdose. Developing a highly effective pain medication without these risks would provide substantial public health benefits. The findings suggest potential for safer opioids.
Applications and Next Steps Researchers suggested DFNZ could potentially be used for pain management in surgery, cancer, and chronic conditions. Further testing, including human clinical trials, is necessary to evaluate its safety and efficacy. The study builds on ongoing efforts to address the opioid crisis, which has been linked to respiratory depression, tolerance, and withdrawal in standard opioids.
